Share ownership Insmed Incorporated

INSM

US4576693075

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:03:03 17/07/2025 pm IST			5-day change	1st Jan Change
102.90 ^USD	-1.61%		+6.85%	+49.59%

16/07	Insmed Insider Sold Shares Worth $699,220, According to a Recent SEC Filing	MT
10/07	Insmed Insider Sold Shares Worth $5,537,460, According to a Recent SEC Filing	MT

Share class: Insmed Incorporated

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	17,89,02,721	17,70,91,433 ( 98.99 %)	0	98.99 %

Major shareholders: Insmed Incorporated

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 10.09 %	1,82,68,122	10.09 %	1 839 M $
Darwin Global Management Ltd. 8.507 %	1,53,97,975	8.507 %	1 550 M $
BlackRock Advisors LLC 8.305 %	1,50,32,724	8.305 %	1 513 M $
T. Rowe Price International Ltd. 7.14 %	1,29,23,541	7.14 %	1 301 M $
Capital Research & Management Co. (International Investors) 3.977 %	71,98,485	3.977 %	724 M $
JPMorgan Investment Management, Inc. 3.511 %	63,54,022	3.511 %	639 M $
STATE STREET CORPORATION 3.175 %	57,47,293	3.175 %	578 M $
Baker Bros. Advisors LP 2.973 %	53,80,626	2.973 %	542 M $
Geode Capital Management LLC 2.369 %	42,88,735	2.369 %	432 M $
Adage Capital Partners GP LLC 1.904 %	34,46,944	1.904 %	347 M $
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	94.96%
Other	10.99%
State Street Corp.	3.18%
Individuals	1.15%
Polar Capital Holdings Plc	0.4%
SEI Investments Co.	0.24%
Schweizerische Nationalbank	0.18%
Manulife Financial Corp.	0.18%
Corebridge Financial, Inc.	0.05%
Skandinaviska Enskilda Banken AB	0.02%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	85.63%
United Kingdom	18.35%
Australia	1.49%
Individuals	1.15%
Norway	1.03%
Canada	0.86%
Germany	0.59%
Denmark	0.58%
France	0.35%
Luxembourg	0.32%
Switzerland	0.31%
Sweden	0.12%
Ireland	0.06%
Hong Kong	0.06%
Austria	0.03%
China	0.03%
Cayman Islands	0.01%
Netherlands	0.01%
Taiwan	0.01%
United Arab Emirates	0.01%

Based on 1000 largest holdings

Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

Employees

1,271

Sector

Biotechnology & Medical Research

Calendar

31/07 - Q2 2025 Earnings Release (Projected)

More about the company